LRRK2 抑制剂在帕金森病方面的研究进展。
A step forward for LRRK2 inhibitors in Parkinson's disease.
机构信息
Royal Veterinary College, London NW1 0TU, UK.
UCL Queen Square Institute of Neurology, London WC1N 3BG, UK.
出版信息
Sci Transl Med. 2022 Jun 8;14(648):eabq7374. doi: 10.1126/scitranslmed.abq7374.
PMID:35675432
Abstract
A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.
摘要
一项针对 LRRK2 的激酶抑制剂的 1 期临床试验为测试 LRRK2 激酶抑制剂在帕金森病中的疗效提供了基础。
Zotero 插件